In a model of transplantation rejection, we have tested whether a graft manipulated to secrete immunomodulators could protect itself from immune destruction. An insulinoma cell line having the NOD genotype but also expressing the neoantigen, SV40 T antigen, was transfected with CTLA4Ig or LFA3Ig to block signals in the co-stimulatory/adhesion pathways. This neoantigen is potent at inducing graft rejection. Secretion of CTLA4Ig and LFA3Ig by transfectants promoted survival of the insulinoma graft in young NOD mice. In immunodeficient mice, cell growth was similar for all transfectants. However, in immunocompetent NOD mice the survival/growth of test grafts was significantly better than that of the controls. Graft survival was enhanced additively, when the two test transfectants were cotransplanted. Endowing the graft the ability to secrete immunomodulators that block individual co-stimulatory/adhesion signals can contribute to transplantation success. Blockade of two signals (CD2 and CD28) in these pathways enhances this success.
An important component of transplantation rejection
several experimental transplantation models, blocking CD28/B7 T-cell co-stimulation has been shown to be is an immune reaction initiated by host T-cell recognition of graft antigens (allo or xeno) on antigen-present-very effective in inhibiting the immune response through the use of a soluble competitive inhibitor, CTLA4Ig, ing cells (APCs). The drugs currently used in clinical transplantation for immunosuppression to prevent rejec-which binds B7 avidly (17, 18, 21, 30, 33) . These studies have demonstrated that in the absence of co-stimulatory tion are not specific for antigen-reactive recipient T lymphocytes and have serious side effects, including toxic-signals, T cells are unresponsive to specific antigen. Occasionally, CTLA4Ig appears to have induced tolerance, ity to organs and increased infections and cancers. Immunosuppression can be made more specific by sev-leading to indefinite allograft survival. In most of these treatments, CTLA4Ig was used systemically. Others eral methods. These include targeting only T cells (e.g., use of OKT3), making only the antigen-specific immune have attempted to reduce the amount of systemic treatment using various models with modest success (3,10, cells to be unresponsive (e.g., tolerization by microchimerism) (26), by targeting only activated T cells (e.g., 11, 27, 28, 31) . We too have attempted to direct the immunosuppression to co-stimulatory signals but in a novel use of anti-CD25 antibodies), or by restricting the immunosuppression geographically (i.e., local immunosup-model; we have genetically modified the graft itself to continually secrete CTLA4Ig in the vicinity of where it pression). Our strategy of genetically modifying the graft to secrete immunosuppressive factors belongs to is needed. We have also broadened the blockade of costimulatory signals by having the graft secrete more than the last method.
For optimal activation of naive T cells, both the T-one co-stimulatory ligand. We hypothesize that the effectiveness of CTLA4Ig cell receptor (TCR) and a co-stimulator molecule must be engaged. The molecules B7-1 (CD80) and B7-2 in enhancing and prolonging allograft survival may be augmented if other co-stimulatory interactions were also (CD86) expressed on APCs deliver potent co-stimulatory signals through CD28 on T cells, resulting in acti-blocked (e.g., LFA3-CD2). CD2 is found on all subsets of T cells and NK cells in humans; T, NK, and some vation of both CD4+ T helper and CD8+ CTL (29). In 176 BRADY, YAMASHITA, AND LEW APC in rats; and T, B, NK, and some APC in mice (4).
LFA-3 interacts with the first extracellular domain of CD2 (25) . The two major ligands for CD2 are LFA-3 and CD48. LFA-3 is a surface glycoprotein distributed widely on T CD2/LFA-3 T-cell co-stimulation can be effectively blocked in vitro by several soluble inhibitors such as and B lymphocytes, erythrocytes (LFA-3 endows sheep erythrocytes to form rosettes around human T cells), en-anti-CD2 (1,35) and anti-LFA-3 (1, 14) . A fusion protein composed of the first domain of human LFA-3 linked to dothelium, platelets, and granulocytes (16) . CD48, the structurally related molecule to LFA-3, is the major li-the Fc of IgG1 has also been effective (6, 22, 25) ; unfortunately, human LFA-3 did not bind mouse CD2 and so gand for CD2 in rodents (7). CD2 is homologous to both LFA-3 and CD48. The first extracellular domain of in vivo experiments in mice were not performed. Simi- larly, there have been several reports that blocking CD2/ have used an insulinoma cell line, NIT, having the NOD genotype but that also expresses the SV40 large T anti-LFA-3 interactions prolongs allograft (4,5,8,16,32) and xenograft (4) survival. Again, all of these models in-gen (13) . Immune rejection against the neoantigen destroys NIT cells in young NOD mice. The extracellular volved systemic treatment to achieve in vivo T-cell suppression and graft prolongation.
domains of mouse CTLA4 and sheep LFA-3 (sLFA3) including their secretory signals were fused to the Fc The CD2 molecule appears to be a good target for immunotherapy because it is expressed on all subsets of portion of IgG2c of NOD (23) . We chose sLFA3 because we found that the sheep isotype binds mouse CD2 T cells, NK cells, and lymphokine-activated killer cells, all known to be effectors of allograft rejection (16) . It is (see below). We then determined whether secretion of CTLA4-2c or LFA3-2c could protect against graft rejec-also the only T-cell surface molecule by which T cells can be activated independently from the TCR/CD3 com-tion that is due to the neoantigen, SV40 T antigen. We also determined whether secretion of these molecules in plex (6). Because T-cell activation requires not only presentation of antigen to the TCR but also the interaction combination could further enhance graft survival. We propose that islets be engineered to secrete im-of T-cell co-stimulatory molecules, these molecules are obvious targets for immunotherapy. These signals are munomodulatory molecules derived from the co-stimulatory signal pathways to confer substantial protection neither antigen specific nor MHC restricted. CD28 and CD2 have been shown to be two important T-cell mole-against immune rejection, and that it is better to block two pathways than only one. It is important that the mol-cules that provide co-stimulatory signals after interaction with the B7 and LFA-3 ligands expressed on APCs.
ecules be produced at the graft site where they are needed, minimizing the need for systemic immunosup-Whereas CD28 seems to be mainly involved in the induction of naive T-cell activation, CD2 may be involved pression. Animal husbandry, cell lines, plasmids, transfections, in both the effector and induction phase of T cells.
Transplantation of islet cells as a source of physio-ELISA, protein purification, SDS-PAGE, and Western blotting have been previously described (20, 24) . The logically regulated insulin may prove a way to cure established type I diabetes mellitus, and the nonobese dia-leader sequence from CD5 was provided by B. Seed, the cDNA encoding murine CTLA4 was provided by P. betic (NOD) mouse is an experimental model for this disease. In our model of transplantation rejection we Lane, and the cDNA encoding sLFA3 was cloned from RNA extracted from Con A activated peripheral blood and sLFA3-2c migrated at 38 K (the minor bands are probably due to differential gylcosylation), 60 K, and 55 mononuclear cells by RT-PCR. Each molecule was then fused to IgG2c Fc and inserted into the pRep7 plasmid K, respectively, under reducing conditions ( Fig. 1B) and 58 K, 110 K, and 100 K, respectively, under nonreduc-(Rous sarcoma virus promoter) (Invitrogen, Carlsbad, CA). The plasmids used for transfections are represented ing conditions using nonreduced standards (Life Technologies, Inc., Gaithersburg, MD) (not shown). The mo-in Figure 1A .
CD5L-2c, CTLA4-2c, and sLFA3-2c in the eukaryo-lecular mass of the polypeptides was higher than calculated due to N-glycosylation of the CH2 domain of tic expression vector pREP7 (Hygromycin resistance cassette) were stably expressed in NIT cells. Superna-IgG2c. The fusion proteins are dimers under nonreducing conditions as the hinge region of mouse IgG2c forms tants from clonal stable transfectants were screened by ELISA and Western blotting. CTLA4-2c and sLFA3-2c two interchain disulphide bridges (not shown). CTLA4-2c and sLFA3-2c from the supernatants of transfectants produce similar levels (1 µg/ml in supernatants from 10 7 cells in 24 h). The control CD5L-2c trans-NIT transfectants were shown to bind B7 and CD2 on mouse splenocytes by flow cytometry (Fig. 1B) . Note fectants secrete about twice this amount. Western blotting of purified proteins showed CD5L-2c, CTLA4-2c, that CD2 is found in both B and T cells in the mouse (cf. CD2 is found on human T cells only). Mouse CBA nontransfected cells ( Fig. 2A) . Secretion of fusion proteins was not altered in vitro in the presence of increas-splenocytes were incubated overnight at 37°C, 5% CO 2 with lipopolysaccharide (20 µg/ml) and dextran sulphate ing glucose concentrations. Viability of the engineered cells was comparable to the unengineered cells in vitro. (50 µg/ml) to activate B cells. Bound fusion proteins were detected with biotinylated anti-mouse IgG2 a b (Igh-Growth characteristics in vivo were determined by injecting cells (5 × 10 6 ) subcutaneously into the left groin 1b) (clone 5.7, Pharmingen, San Diego, CA) (this antibody recongizes IgG2c), followed by phycoerythrin-of irradiated (and hence immunodeficient) NOD/Lt mice. Growth was similar for NIT.CTLA4-2c, NIT.-conjugated streptavidin (Caltag, San Francisco, CA).
To determine whether transfected cells may have al-sLFA3-2c, and NIT.CD5L-2c ( Fig. 2B) . Growth was assessed visually, by palpation, and by imminent host tered characteristics, insulin secretion and growth characteristics were analyzed. Transfected and nontransfec-mortality. The latter occurs because NIT insulinoma cells secrete insulin that is not regulated. As the graft ted cells (5 × 10 6 ) were grown for 3 days, and the supernatants were tested for insulin levels by radioim-grows, more insulin is produced: the mice develop profound hypoglycemia and are sacrificed when blood glu-munoassay. A Phadeseph Insulin Radioimmunoassay Kit was obtained from Pharmacia (Uppsala, Sweden) and cose falls below 3 mmol/L or when moribund. Thus, successful grafting leads to the eventual death of the the assay was performed according to the manufacturer's instructions. Insulin secretion was comparable in all host as our experimental read-out. The SV40 T neoantigen induces a strong immune re-transfected cells, although slightly less than that of the sponse such that NIT cells are eliminated from normal
We have shown that by mixing two insulinoma cell lines that are secreting different co-stimulatory inhibi-NOD mice and thus no tumors develop. The growth and survival of CTLA4-2c-and sLFA3-2c-transfected cells tors, the mixed graft is more effective in conferring protection against immune attack. It would be interesting is significantly superior to control transfectants when injected subcutaneously into NOD mice (i.e., CD5L-2c to determine whether having the one cell secreting both co-stimulatory signals (i.e., doubly transfected cells) or plus CTLA4-2c or sLFA3-2c vs. CD5L-2c alone, 2 × 10 7 cells total) (p = 0.067 and p = 0.009, respectively; even several co-stimulatory inhibitors can improve this strategy. The techniques of transgenesis or viral trans-log-rank test) (Fig. 3) . By combining CTLA4-2c-and sLFA3-2c-transfected cells (1 × 10 7 of each), growth and duction to introduce these molecules into the graft may allow successful organ transplantation for an allograft or survival of NIT cells is superior to that achieved by individual fusion protein secretion (CTLA4-2c vs. com-xenograft setting. In fact, islet xenografts adenovirally transduced with CTLA4Ig have shown modest protec-bined; p = 0.025; sLFA3-2c vs. combined, p = 0.170) ( Fig. 3) . Histopathologically, we were unable to com-tion from rejection (10). There is a multitude of cell surface antigens involved in T-cell activation and it may pare tumors with CD5L-2c control tumors as the grafts never became established and were rejected early. How-require targeting several co-stimulatory interactions to effectively block graft rejection. ever, the CTLA4-2c and sLFA3-2c tumors were well established, showing many mitotic figures, vasculature, ACKNOWLEDGMENTS: This work was supported by the and blood-filled lakes (Fig. 4 ). There was very little NH&MRC of Australia, Diabetes Australia, and a JDFI-NIH program grant. mononuclear infiltration. The histological appearance of the grafts confirms that secretion of these molecules had REFERENCES modulating effects on the immune response.
This study has shown that genetic modification of
